Literature DB >> 31085700

Low-Dose IFNγ Induces Tumor Cell Stemness in Tumor Microenvironment of Non-Small Cell Lung Cancer.

Mengjia Song1,2,3, Yu Ping1,2, Kai Zhang1,2, Li Yang1,2, Feng Li1,2, Chaoqi Zhang1,2,4, Shaoyan Cheng1,2, Dongli Yue1,2, Nomathamsanqa Resegofetse Maimela1,2, Jiao Qu1,2, Shasha Liu1,2, Ting Sun1, Zihai Li5, Jianchuan Xia3, Bin Zhang6, Liping Wang7, Yi Zhang8,2.   

Abstract

IFNγ is conventionally recognized as an inflammatory cytokine that plays a central role in antitumor immunity. Although it has been used clinically to treat a variety of malignancies, low levels of IFNγ in the tumor microenvironment (TME) increase the risk of tumor metastasis during immunotherapy. Accumulating evidence suggests that IFNγ can induce cancer progression, yet the mechanisms underlying the controversial role of IFNγ in tumor development remain unclear. Here, we reveal a dose-dependent effect of IFNγ in inducing tumor stemness to accelerate cancer progression in patients with a variety of cancer types. Low levels of IFNγ endowed cancer stem-like properties via the intercellular adhesion molecule-1 (ICAM1)-PI3K-Akt-Notch1 axis, whereas high levels of IFNγ activated the JAK1-STAT1-caspase pathway to induce apoptosis in non-small cell lung cancer (NSCLC). Inhibition of ICAM1 abrogated the stem-like properties of NSCLC cells induced by the low dose of IFNγ both in vitro and in vivo. This study unveils the role of low levels of IFNγ in conferring tumor stemness and elucidates the distinct signaling pathways activated by IFNγ in a dose-dependent manner, thus providing new insights into cancer treatment, particularly for patients with low expression of IFNγ in the TME. SIGNIFICANCE: These findings reveal the dose-dependent effect of IFNγ in inducing tumor stemness and elucidate the distinct molecular mechanisms activated by IFNγ in a dose-dependent manner. ©2019 American Association for Cancer Research.

Entities:  

Year:  2019        PMID: 31085700     DOI: 10.1158/0008-5472.CAN-19-0596

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  30 in total

1.  Identification of BST2 Contributing to the Development of Glioblastoma Based on Bioinformatics Analysis.

Authors:  Yang Kong; Zhiwei Xue; Haiying Wang; Guangqiang Cui; Anjing Chen; Jie Liu; Jian Wang; Xingang Li; Bin Huang
Journal:  Front Genet       Date:  2022-07-05       Impact factor: 4.772

2.  Blockade or Deletion of IFNγ Reduces Macrophage Activation without Compromising CAR T-cell Function in Hematologic Malignancies.

Authors:  Stefanie R Bailey; Sonika Vatsa; Rebecca C Larson; Amanda A Bouffard; Irene Scarfò; Michael C Kann; Trisha R Berger; Mark B Leick; Marc Wehrli; Andrea Schmidts; Harrison Silva; Kevin A Lindell; Ashley Demato; Kathleen M E Gallagher; Matthew J Frigault; Marcela V Maus
Journal:  Blood Cancer Discov       Date:  2022-03-01

3.  CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours.

Authors:  Rebecca C Larson; Michael C Kann; Stefanie R Bailey; Nicholas J Haradhvala; Paula Montero Llopis; Amanda A Bouffard; Irene Scarfó; Mark B Leick; Korneel Grauwet; Trisha R Berger; Kai Stewart; Praju Vikas Anekal; Max Jan; Julia Joung; Andrea Schmidts; Tamara Ouspenskaia; Travis Law; Aviv Regev; Gad Getz; Marcela V Maus
Journal:  Nature       Date:  2022-04-13       Impact factor: 69.504

4.  ILC1s control leukemia stem cell fate and limit development of AML.

Authors:  Zhenlong Li; Rui Ma; Shoubao Ma; Lei Tian; Ting Lu; Jianying Zhang; Bethany L Mundy-Bosse; Bin Zhang; Guido Marcucci; Michael A Caligiuri; Jianhua Yu
Journal:  Nat Immunol       Date:  2022-04-29       Impact factor: 31.250

5.  Key Genes And Pathways Controlled By E2F1 In Human Castration-Resistant Prostate Cancer Cells.

Authors:  Qingniao Zhou; Chengbang Wang; Yuanyuan Zhu; Qunying Wu; Yonghua Jiang; Yuanjie Huang; Yanling Hu
Journal:  Onco Targets Ther       Date:  2019-10-31       Impact factor: 4.147

6.  Regulatory T cells promote glioma cell stemness through TGF-β-NF-κB-IL6-STAT3 signaling.

Authors:  Shasha Liu; Chaoqi Zhang; Boqiao Wang; Huanyu Zhang; Guohui Qin; Congcong Li; Ling Cao; Qun Gao; Yu Ping; Kai Zhang; Jingyao Lian; Qitai Zhao; Dan Wang; Zhen Zhang; Xuan Zhao; Li Yang; Lan Huang; Bo Yang; Yi Zhang
Journal:  Cancer Immunol Immunother       Date:  2021-02-12       Impact factor: 6.968

7.  MiR-342 controls Mycobacterium tuberculosis susceptibility by modulating inflammation and cell death.

Authors:  Beibei Fu; Xiaoyuan Lin; Shun Tan; Rui Zhang; Weiwei Xue; Haiwei Zhang; Shanfu Zhang; Qingting Zhao; Yu Wang; Kelly Feldman; Lei Shi; Shaolin Zhang; Weiqi Nian; Krishna Chaitanya Pavani; Zhifeng Li; Xingsheng Wang; Haibo Wu
Journal:  EMBO Rep       Date:  2021-07-20       Impact factor: 9.071

Review 8.  Bidirectional Crosstalk Between Cancer Stem Cells and Immune Cell Subsets.

Authors:  Luise Müller; Antje Tunger; Ioana Plesca; Rebekka Wehner; Achim Temme; Dana Westphal; Friedegund Meier; Michael Bachmann; Marc Schmitz
Journal:  Front Immunol       Date:  2020-02-05       Impact factor: 7.561

Review 9.  The Interactions Between Cancer Stem Cells and the Innate Interferon Signaling Pathway.

Authors:  Laura Martin-Hijano; Bruno Sainz
Journal:  Front Immunol       Date:  2020-03-31       Impact factor: 7.561

10.  Galectin-3 favours tumour metastasis via the activation of β-catenin signalling in hepatocellular carcinoma.

Authors:  Mengjia Song; Qiuzhong Pan; Jieying Yang; Junyi He; Jianxiong Zeng; Shaoyan Cheng; Yue Huang; Zi-Qi Zhou; Qian Zhu; Chaopin Yang; Yulong Han; Yan Tang; Hao Chen; De-Sheng Weng; Jian-Chuan Xia
Journal:  Br J Cancer       Date:  2020-08-17       Impact factor: 9.075

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.